NLRP3 and type 2 diabetes mellitus: However, MCC950-treated T2DM rats did not show statistically significant changes in blood glucose and body weight levels, suggesting that MCC950 selectively binds to the ATPase structural domain of NLRP3 to block the assembly of inflammasome and does not interfere with key nodes of the insulin signaling pathway at therapeutic doses (0.01-10 mM), and therefore does not exacerbate the core pathology of T2DM when treating DR --insulin resistance, which is consistent with the findings of liu’s group42.